CL2025000596A1 - Formas co-cristalinas de 4-[4-[3-cloro-4-[1-(2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con ácido gálico y/o nicotinamida. - Google Patents
Formas co-cristalinas de 4-[4-[3-cloro-4-[1-(2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con ácido gálico y/o nicotinamida.Info
- Publication number
- CL2025000596A1 CL2025000596A1 CL2025000596A CL2025000596A CL2025000596A1 CL 2025000596 A1 CL2025000596 A1 CL 2025000596A1 CL 2025000596 A CL2025000596 A CL 2025000596A CL 2025000596 A CL2025000596 A CL 2025000596A CL 2025000596 A1 CL2025000596 A1 CL 2025000596A1
- Authority
- CL
- Chile
- Prior art keywords
- pyrazolo
- carbonitrile
- triazol
- pyridin
- piperidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263404232P | 2022-09-07 | 2022-09-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2025000596A1 true CL2025000596A1 (es) | 2025-04-25 |
Family
ID=88204177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025000596A CL2025000596A1 (es) | 2022-09-07 | 2025-03-04 | Formas co-cristalinas de 4-[4-[3-cloro-4-[1-(2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con ácido gálico y/o nicotinamida. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240116932A1 (enExample) |
| EP (1) | EP4584270A1 (enExample) |
| JP (2) | JP7541606B2 (enExample) |
| KR (1) | KR20250057022A (enExample) |
| CN (1) | CN120187720A (enExample) |
| AR (1) | AR130417A1 (enExample) |
| AU (1) | AU2023338199A1 (enExample) |
| CA (1) | CA3266872A1 (enExample) |
| CL (1) | CL2025000596A1 (enExample) |
| CO (1) | CO2025002467A2 (enExample) |
| CR (1) | CR20250077A (enExample) |
| DO (1) | DOP2025000054A (enExample) |
| IL (1) | IL319342A (enExample) |
| PE (1) | PE20251400A1 (enExample) |
| TW (1) | TWI862146B (enExample) |
| WO (1) | WO2024054814A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025259519A1 (en) | 2024-06-13 | 2025-12-18 | Eli Lilly And Company | Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007067727A2 (en) | 2005-12-08 | 2007-06-14 | Ssci, Inc. | Metronidazole cocrystals and imipramine cocrystals |
| PH12012000132A1 (en) | 2011-06-09 | 2014-10-20 | Servier Lab | New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them |
| CN102964384B (zh) | 2012-11-09 | 2015-06-24 | 中山大学 | 阿德福韦酯没食子酸共晶及其制备方法和组合物 |
| JP2021523876A (ja) | 2018-02-13 | 2021-09-09 | トランスジェネックス ナノバイオテック、インコーポレイテッド | 癌治療のためのタミバロテンの新規の結晶形態 |
| US12180207B2 (en) * | 2018-12-19 | 2024-12-31 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases |
| CN111574359A (zh) | 2019-02-19 | 2020-08-25 | 愈磐生物科技（苏州）有限公司 | 乐伐替尼-没食子酸共晶晶型及其应用 |
| CN113943284B (zh) | 2020-07-15 | 2023-12-19 | 中国医学科学院药物研究所 | 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途 |
| TW202402754A (zh) | 2021-03-04 | 2024-01-16 | 美商美國禮來大藥廠 | Fgfr3抑制劑化合物 |
-
2023
- 2023-09-06 CN CN202380077374.0A patent/CN120187720A/zh active Pending
- 2023-09-06 CR CR20250077A patent/CR20250077A/es unknown
- 2023-09-06 KR KR1020257010708A patent/KR20250057022A/ko not_active Ceased
- 2023-09-06 PE PE2025000482A patent/PE20251400A1/es unknown
- 2023-09-06 US US18/462,286 patent/US20240116932A1/en active Pending
- 2023-09-06 IL IL319342A patent/IL319342A/en unknown
- 2023-09-06 CA CA3266872A patent/CA3266872A1/en active Pending
- 2023-09-06 AU AU2023338199A patent/AU2023338199A1/en active Pending
- 2023-09-06 EP EP23777475.7A patent/EP4584270A1/en active Pending
- 2023-09-06 WO PCT/US2023/073508 patent/WO2024054814A1/en not_active Ceased
- 2023-09-07 JP JP2023145013A patent/JP7541606B2/ja active Active
- 2023-09-07 TW TW112133993A patent/TWI862146B/zh active
- 2023-09-07 AR ARP230102376A patent/AR130417A1/es unknown
-
2024
- 2024-08-16 JP JP2024136962A patent/JP2024153948A/ja active Pending
-
2025
- 2025-02-28 CO CONC2025/0002467A patent/CO2025002467A2/es unknown
- 2025-03-04 CL CL2025000596A patent/CL2025000596A1/es unknown
- 2025-03-06 DO DO2025000054A patent/DOP2025000054A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2025000054A (es) | 2025-03-31 |
| CR20250077A (es) | 2025-04-02 |
| TW202428260A (zh) | 2024-07-16 |
| TWI862146B (zh) | 2024-11-11 |
| CN120187720A (zh) | 2025-06-20 |
| CO2025002467A2 (es) | 2025-03-17 |
| PE20251400A1 (es) | 2025-05-22 |
| JP2024037713A (ja) | 2024-03-19 |
| JP2024153948A (ja) | 2024-10-29 |
| JP7541606B2 (ja) | 2024-08-28 |
| WO2024054814A1 (en) | 2024-03-14 |
| AR130417A1 (es) | 2024-12-04 |
| KR20250057022A (ko) | 2025-04-28 |
| US20240116932A1 (en) | 2024-04-11 |
| IL319342A (en) | 2025-05-01 |
| AU2023338199A1 (en) | 2025-03-20 |
| EP4584270A1 (en) | 2025-07-16 |
| CA3266872A1 (en) | 2024-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| CL2023001738A1 (es) | Inhibidores de prmt5 | |
| CL2025000596A1 (es) | Formas co-cristalinas de 4-[4-[3-cloro-4-[1-(2-piridil)-2-hidroxi-etoxi]pirazolo[1,5-a]piridin-6-il]-5-metil-triazol-1-il]piperidina-1-carbonitrilo con ácido gálico y/o nicotinamida. | |
| GT200900056A (es) | Benzoxazoles y oxazolopiridinas utiles como inhibidores de la quinasa janus | |
| EP4523755A3 (en) | Quinazoline derivatives as antitumor agents | |
| Alhaider et al. | Caffeine prevents sleep loss‐induced deficits in long‐term potentiation and related signaling molecules in the dentate gyrus | |
| CL2011000880A1 (es) | Compuestos derivados de pirazolo[1,5-a]pirimidin-3-il, inhibidores de tirosina de la familia trk cinasa; proceso para la preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del dolor y del cancer. | |
| MX2019013260A (es) | Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas. | |
| MX2021009444A (es) | Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7. | |
| UY27811A1 (es) | 3-aminopirazoles n-sustituidos como inhibidores para el tratamiento de los desórdenes proliferativos de las células. | |
| UY39477A (es) | Compuestos espiro heterocíclicos y métodos de uso | |
| CO2023007677A2 (es) | Derivados de pyrazolo[1,5-a]pirazina como inhibidores de la btk | |
| ECSP077994A (es) | Aminopirimidinas como moduladores de cinasa | |
| ECSP22009803A (es) | [1,2,4]triazolo[1,5-c]quinazolin-5-aminas | |
| Kranz et al. | Phosphodiesterase type 4 inhibitor rolipram improves survival of spiral ganglion neurons in vitro | |
| AR132251A1 (es) | Derivados de 5-amino-6,8-dihidro-1h-furo[3,4-d]pirrolo[3,2-b]piridin-2-carboxamida como inhibidores cooperativos con mta de prmt5 | |
| BR112023011451A2 (pt) | Inibidores de alk-5 e seus usos | |
| MX2024014995A (es) | Macrociclos que contienen indazol y su uso | |
| CL2024003731A1 (es) | Compuestos tricíclicos de triazolo, inhibidores de dgk; uso para tratar cáncer. | |
| CR20240533A (es) | Macrociclos de indazol y su uso | |
| UY31866A (es) | Combinaciones farmacéuticas comprendiendo los compuestos 3-z[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilene]-6-metoxicarbonil-2-indolinona y el ácido n-[4-[2-(2-amino-4,7-dihidro-4-oxo-1h-pirrolo [2,3-d] pirimidin-5-il)etil]benzoil]-l-glutamico; sus sales farmacéuticamente aceptables y aplicaciones | |
| UY39865A (es) | Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer | |
| CR20250054A (es) | Inhibidores de tirosina cinasa 2 y usos de estos | |
| CO2023013406A2 (es) | Análogos de rifamicina en combinación con vancomicina y usos de los mismos | |
| KR20190063792A (ko) | 슈반세포 분화용 배지 조성물 및 상기 배지 조성물을 이용한 체세포로부터 슈반세포로의 분화 방법 |